Key Highlights

  • Cochlear implant units increased 5% to 56,692 in FY26.
  • Sales Revenue reached AUD 2.34bn as constant-currency revenue rose 2%.
  • Underlying net profit declined 22% to AUD 322.4mn.
  • FY27 guidance targets underlying net profit of AUD 330mn to AUD 350mn.

Higher implant volumes did not translate into higher FY26 Earnings for Cochlear. Cochlear (ASX:COH) recorded growth in implant units and constant-currency revenue, but pricing changes, expenditure and a lower gross Margin reduced underlying profit. Management’s FY27 range points to a measured recovery while product adoption, service revenue and market-specific reimbursement remain in focus.

Company Business

Cochlear designs and supports implantable hearing devices. Revenue comes from cochlear implants, services for existing recipients, including sound-processor upgrades and accessories, and acoustics products such as bone-conduction systems. The company sells across developed and emerging markets, making surgical activity, reimbursement, product cycles and currency movements relevant to reported performance.

Sector Context

Cochlear reported its FY26 result on 17 August 2026. Sales revenue of AUD 2,343mn grew 2% in constant currency, though currency translation left it 1% lower in reported terms. Statutory net profit fell 62% to AUD 147.3mn, reflecting a AUD 109.1mn non-cash writedown on portfolio company Epiminder and about AUD 66mn of cloud-related spending.

The board declared a final Dividend of AUD 1.30 per share, 40% lower than the prior year, bringing the FY26 total to AUD 3.45 per share, down 20%. Cochlear implant units of 56,692 were up 5% year on year, but implant revenue of AUD 1,435mn was flat in constant currency, reflecting weaker pricing in China and emerging markets. Services revenue of AUD 635mn grew 6% and acoustics revenue of AUD 273mn rose 1%, both in constant currency.

Emerging market sales declined 2% overall. Gross margin contracted to 71% from 74%, and the net profit margin of 14% sat below the company's 18% medium-term objective. Cash performance moved the other way: Operating Cash Flow of AUD 368mn was AUD 130mn higher, free cash flow more than doubled to AUD 263.5mn, and Capital Expenditure was AUD 91mn.

The Nucleus Nexa system accounted for more than 95% of developed market implant sales by June 2026, carrying an average 3% price increase.

Risks to Consider

Reimbursement decisions and procurement reform in large markets can reset pricing with little notice, as China has demonstrated. A majority of revenue is earned offshore, so the Australian dollar materially affects reported results. Elective surgery capacity, competitor product cycles, regulatory approvals and the cost of sustained Research and Development all bear on outcomes, and the shares continue to trade on a valuation that assumes recovery.

What to Watch Next

Guidance for FY27 is for low single-digit constant currency revenue growth and underlying net profit of AUD 330-350mn, an increase of 2% to 9%, with gross margin of 70-71%. Management also flagged a 15% lift in research and development spending. Whether margin stabilises, how Chinese volume-based procurement evolves, and the pace of Nexa-driven upgrade activity within the services base are the identifiable markers.

The position is mixed: unit volumes still growing, revenue broadly flat, Underlying Profit down 22%, dividends cut, yet free cash flow more than doubled. FY27 guidance points to a modest earnings recovery rather than a rebound. That combination of a reset base and a cautious guide is why Cochlear could be an ASX healthcare stock to watch.